Thyroid's secretory capacity

Last updated

Thyroid's secretory capacity
Reference ranges for TSH, FT4, JTI and SPINA-GT.svg
Reference ranges for SPINA-GT and other thyroid function tests
Synonyms SPINA-GT, GT, T4 output, thyroid hormone output, thyroid's incretory capacity, functional thyroid capacity [1]
Reference range 1.41–8.67 pmol/s
Test ofMaximum amount of T4 produced by the thyroid in one second
MeSH D013960
LOINC 82368-2

Thyroid's secretory capacity (GT, also referred to as thyroid's incretory capacity, maximum thyroid hormone output, T4 output or, if calculated from serum levels of thyrotropin and thyroxine, as SPINA-GT [lower-alpha 1] ) is the maximum stimulated amount of thyroxine that the thyroid can produce in a given time-unit (e.g. one second). [2] [3]

Contents

How to determine GT

Experimentally, GT can be determined by stimulating the thyroid with a high thyrotropin concentration (e.g. by means of rhTSH, i.e. recombinant human thyrotropin) and measuring its output in terms of T4 production, or by measuring the serum concentration of protein-bound iodine-131 after administration of radioiodine. [4] These approaches are, however, costly and accompanied by significant exposure to radiation. [5]

In vivo, GT can also be estimated from equilibrium levels of TSH and T4 or free T4. In this case it is calculated with

or

[TSH]: Serum thyrotropin concentration (in mIU/L or μIU/mL)
[FT4]: Serum free T4 concentration (in pmol/L)
[TT4]: Serum total T4 concentration (in nmol/L)
: Theoretical (apparent) secretory capacity (SPINA-GT)
: Dilution factor for T4 (reciprocal of apparent volume of distribution, 0.1 L−1)
: Clearance exponent for T4 (1.1e-6 sec−1), i. e., reaction rate constant for degradation
K41: Binding constant T4-TBG (2e10 L/mol)
K42: Binding constant T4-TBPA (2e8 L/mol)
DT: EC50 for TSH (2.75 mU/L) [2] [6]

The method is based on mathematical models of thyroid homeostasis. [2] [3] Calculating the secretory capacity with one of these equations is an inverse problem. Therefore, certain conditions (e.g. stationarity) have to be fulfilled to deliver a reliable result.

Specific secretory capacity

The ratio of SPINA-GT and thyroid volume VT (as determined e.g. by ultrasonography)

,

i.e.

or

is referred to as specific thyroid capacity (SPINA-GTs). [7] It is a measure for how much one millilitre of thyroid tissue can produce under conditions of maximum stimulation. Thereby, SPINA-GTs is an estimate for the endocrine quality of thyroid tissue.[ citation needed ]

Reference Range

Percentiles for thyroid's secretory capacity (SPINA-GT) along with reference ranges for Jostel's TSH index (TSHI or JTI) and univariable reference ranges for thyrotropin (TSH) and free thyroxine (FT4), shown in the two-dimensional phase plane defined by serum concentrations of TSH and FT4. SPINA-GT percentiles.svg
Percentiles for thyroid's secretory capacity (SPINA-GT) along with reference ranges for Jostel's TSH index (TSHI or JTI) and univariable reference ranges for thyrotropin (TSH) and free thyroxine (FT4), shown in the two-dimensional phase plane defined by serum concentrations of TSH and FT4.
Lower limitUpper limitUnit
1.41 [2] 8.67 [2] pmol/s

The equations and their parameters are calibrated for adult humans with a body mass of 70 kg and a plasma volume of ca. 2.5 L. [2]

Clinical significance

Validity

SPINA-GT is elevated in primary hyperthyroidism [8] [9] and reduced in both primary hypothyroidism [10] [11] [12] [9] and untreated autoimmune thyroiditis. [13] It has been observed to correlate (with positive direction) to resting energy expenditure, [14] resting heart rate, [15] the colour Doppler ultrasound pattern [16] and thyroid volume, [2] [7] and (with negative direction) to thyroid autoantibody titres, which reflect organ destruction due to autoimmunity. [17] Elevated SPINA-GT in Graves' disease is reversible with antithyroid treatment. [14] While SPINA-GT is significantly altered in primary thyroid disorders, it is insensitive to disorders of secondary nature (e.g. pure pituitary diseases). [3]

Reliability

In silico experiments with Monte Carlo simulations demonstrated that both SPINA-GT and SPINA-GD can be estimated with sufficient reliability, even if laboratory assays have limited accuracy. [3] This was confirmed by longitudinal in vivo studies that showed that GT has lower intraindividual variation (i.e. higher reliability) than TSH, FT4 or FT3. [18]

Clinical utility

In clinical trials SPINA-GT was significantly elevated in patients with Graves' disease and toxic adenoma compared to normal subjects. [2] [8] [19] It is also elevated in diffuse and nodular goiters, and reduced in untreated autoimmune thyroiditis. [2] [13] In patients with toxic adenoma it has higher specificity and positive likelihood ratio for diagnosis of thyrotoxicosis than serum concentrations of thyrotropin, free T4 or free T3. [2] GT's specificity is also high in thyroid disorders of secondary or tertiary origin. [3]

Calculating SPINA-GT has proved to be useful in challenging clinical situations, e.g. for differential diagnosis of subclinical hypothyroidism and elevated TSH concentration due to type 2 allostatic load (as it is typical for obesity and certain psychiatric diseases). For this purpose, its usage has been recommended in sociomedical assessment. [20]

Pathophysiological and therapeutic implications

In patients suffering from toxic adenoma, toxic multinodular goitre and Graves’ disease radioiodine therapy leads to a significant decrease of the initially elevated SPINA-GT. [19]

Correlation of SPINA-GT with creatinine clearance suggests a negative influence of uremic toxins on thyroid biology. [21] [22] In the initial phase of major non-thyroidal illness syndrome (NTIS) SPINA-GT may be temporarily elevated. [23] [24] In chronic NTIS [25] as well as in certain non-critical chronic diseases, e.g. chronic fatigue syndrome [26] [27] or asthma [28] SPINA-GT is slightly reduced.

According to the results of a community-based study in China it was associated to sleep duration and exercise habits. [29] With respect to iodine supply, it showed a complex U-shaped pattern, being reduced in subjects consuming iodine-rich food, but elevated in situations of iodine excess. [29] In two other studies from China, SPINA-GT correlated with negative direction to markers of obesity including body mass index, waist circumference and waist to hip ratio. [30] [31] This doesn't seem to be the case, however, in Western populations. [32]

In women, therapy with Metformin results in increased SPINA-GT, in parallel to improved insulin sensitivity. [33] [34] This observation was reproducible in men with hypogonadism, but not in men with normal testosterone concentrations,. [35] In postmenopausal women this effect was only observed in subjects on oestradiol replacement therapy. [36] Therefore, the described phenomenon seems to depend on an interaction of metformin with sex hormones. [35] [37] In hyperthyroid [8] men both SPINA-GT and SPINA-GD negatively correlate to erectile function, intercourse satisfaction, orgasmic function and sexual desire. Likewise, in women with thyrotoxicosis elevated thyroid's secretory capacity predicts depression and sexual dysfunction. [38] Conversely, in androgen-deficient men with concomitant autoimmune thyroiditis, substitution therapy with testosterone leads to a decrease in thyroid autoantibody titres and an increase in SPINA-GT. [39] In a large study from mainland China, SPINA-GT was elevated in certain psychiatric diseases including bipolar disorder and schizophrenia. [40] In bipolar disorder with manic or mixed episodes it was higher than in cases with depressive episodes. [40]

SPINA-GT is reduced in persons suffering from hidradenitis suppurativa compared to healthy controls with the same sex and age distribution. [41] This phenomenon has been ascribed to B-cell-mediated hypothyroidism, i.e. hypothyroid Graves' disease due to inhibiting TSH receptor autoantibodies (iTRAb). [41]

In patients with autoimmune thyroiditis a gluten-free diet results in increased SPINA-GT (in parallel to sinking autoantibody titres). [42] Statin therapy has the same effect, but only if supply with vitamin D is sufficient. [43] Accordingly, substitution therapy with 25-hydroxyvitamin D leads to rising secretory capacity. [44] [45] [46] [47] This effect is potentiated by substitution therapy with myo-inositol [48] and selenomethionine [44] [45] [49] or, in women, with dehydroepiandrosterone, [50] but impaired in males with early-onset androgenic alopecia. [51] The effects of vitamin D and selenomethionine are attenuated in hyperprolactinaemia, suggesting an inhibitory effect of prolactin. [52] Although both vitamin D supplementation and gluten-free diet result in increased SPINA-GT, there seems to be a complex interaction between both therapeutic measures, since vitamin D treatment is only able to elevate the thyroid's secretory capacity in subjects not following any dietary recommendation. [53]

On the other hand, men treated with spironolactone are faced with decreasing SPINA-GT (in addition to rising thyroid antibody titres). [54] It has, therefore, been concluded that spironolactone may aggravate thyroid autoimmunity in men. [54]

In subjects with type 2 diabetes, treatment with beta blockers resulted in decreased SPINA-GT, suggesting sympathetic innervation to contribute to the control of thyroid function. [55] In diabetic women, but not in men, SPINA-GT shows a positive correlation to the β-C-terminal cross-linked telopeptides of type I collagen (β-CTX), a marker of bone resorption. [56] In both diabetic and non-diabetic persons it correlates (negatively) with age and (positively) with the concentrations of troponin T and HbA1c. [57]

SPINA-GT correlates to mechanical pain sensitivity (MPS) in quantitative sensory testing (QST) and to measures of respiratory arrhythmia in the analysis of heart rate variability, indicating a potential link to both sensorimotor and autonomic neuropathy. [58]

A study in euthyroid subjects with structural heart disease found that increased SPINA-GT predicts the risk of malignant arrhythmia including ventricular fibrillation and ventricular tachycardia. [59] This applies to both incidence and event-free survival. [59] Likewise, SPINA-GT is elevated in a significant subgroup of patients with takotsubo syndrome, [60] especially in non-survivors. [61] A stress-mediated effect on SPINA-GT is also suggested by the observation that it is increased in persons with a history of psychological trauma. [62] On the other hand, two studies found negative correlation between SPINA-GT and markers of dispersion in cardiac repolarisation, including Tp-e interval, JT interval, Tp-e/ QT ratio and Tp-e/QTc ratio. These results suggest that reduced thyroid function may trigger cardiovascular mortality as well. [63] [9]

Among subjects with Parkinson's disease, SPINA-GT is significantly elevated in tremor-dominant and mixed subtypes compared to the akinetic-rigid type. [64]

Specific secretory capacity (SPINA-GTs) is reduced in obesity [2] and autoimmune thyroiditis. [7] [65]

Endocrine disruptors may affect stimulated thyroid output, as demonstrated by a positive correlation of SPINA-GT with exposure to 2-hydroxynaphthalene (2-NAP), [66] urinary mercury concentration [67] and the excretion of certain phthalate metabolites, [68] and negative correlation with combined exposure to polycyclic aromatic hydrocarbons (PAHs) [66] and nickel. [69] Additionally, SPINA-GT was altered in young people exposed to butylparaben. [70]

See also

Notes

  1. ↑ SPINA is an acronym for "structure parameter inference approach".

Related Research Articles

<span class="mw-page-title-main">Hyperthyroidism</span> Clinical syndrome caused by excessive thyroid hormone

Hyperthyroidism is the condition that occurs due to excessive production of thyroid hormones by the thyroid gland. Thyrotoxicosis is the condition that occurs due to excessive thyroid hormone of any cause and therefore includes hyperthyroidism. Some, however, use the terms interchangeably. Signs and symptoms vary between people and may include irritability, muscle weakness, sleeping problems, a fast heartbeat, heat intolerance, diarrhea, enlargement of the thyroid, hand tremor, and weight loss. Symptoms are typically less severe in the elderly and during pregnancy. An uncommon but life-threatening complication is thyroid storm in which an event such as an infection results in worsening symptoms such as confusion and a high temperature; this often results in death. The opposite is hypothyroidism, when the thyroid gland does not make enough thyroid hormone.

<span class="mw-page-title-main">Hypothyroidism</span> Insufficient production of thyroid hormones by the thyroid gland

Hypothyroidism is a disorder of the endocrine system in which the thyroid gland does not produce enough thyroid hormones. It can cause a number of symptoms, such as poor ability to tolerate cold, extreme fatigue, muscle aches, constipation, slow heart rate, depression, and weight gain. Occasionally there may be swelling of the front part of the neck due to goitre. Untreated cases of hypothyroidism during pregnancy can lead to delays in growth and intellectual development in the baby or congenital iodine deficiency syndrome.

Thyroid-stimulating hormone (also known as thyrotropin, thyrotropic hormone, or abbreviated TSH) is a pituitary hormone that stimulates the thyroid gland to produce thyroxine (T4), and then triiodothyronine (T3) which stimulates the metabolism of almost every tissue in the body. It is a glycoprotein hormone produced by thyrotrope cells in the anterior pituitary gland, which regulates the endocrine function of the thyroid.

<span class="mw-page-title-main">Hashimoto's thyroiditis</span> Autoimmune disease

Hashimoto's thyroiditis, also known as chronic lymphocytic thyroiditis and Hashimoto's disease, is an autoimmune disease in which the thyroid gland is gradually destroyed. A slightly broader term is autoimmune thyroiditis, identical other than that it is also used to describe a similar condition without a goiter.

<span class="mw-page-title-main">Levothyroxine</span> Thyroid hormone

Levothyroxine, also known as L-thyroxine, is a synthetic form of the thyroid hormone thyroxine (T4). It is used to treat thyroid hormone deficiency (hypothyroidism), including a severe form known as myxedema coma. It may also be used to treat and prevent certain types of thyroid tumors. It is not indicated for weight loss. Levothyroxine is taken orally (by mouth) or given by intravenous injection. Levothyroxine has a half-life of 7.5 days when taken daily, so about six weeks is required for it to reach a steady level in the blood.

<span class="mw-page-title-main">Thyroid disease</span> Medical condition

Thyroid disease is a medical condition that affects the function of the thyroid gland. The thyroid gland is located at the front of the neck and produces thyroid hormones that travel through the blood to help regulate many other organs, meaning that it is an endocrine organ. These hormones normally act in the body to regulate energy use, infant development, and childhood development.

Thyroid storm is a rare but severe and life-threatening complication of hyperthyroidism. It occurs when an overactive thyroid leads to hypermetabolism, which can cause death from cardiac arrest or multiple organ failure.

Thyroid function tests (TFTs) is a collective term for blood tests used to check the function of the thyroid. TFTs may be requested if a patient is thought to suffer from hyperthyroidism or hypothyroidism, or to monitor the effectiveness of either thyroid-suppression or hormone replacement therapy. It is also requested routinely in conditions linked to thyroid disease, such as atrial fibrillation and anxiety disorder.

<span class="mw-page-title-main">Graves' ophthalmopathy</span> Medical condition

Graves' ophthalmopathy, also known as thyroid eye disease (TED), is an autoimmune inflammatory disorder of the orbit and periorbital tissues, characterized by upper eyelid retraction, lid lag, swelling, redness (erythema), conjunctivitis, and bulging eyes (exophthalmos). It occurs most commonly in individuals with Graves' disease, and less commonly in individuals with Hashimoto's thyroiditis, or in those who are euthyroid.

<span class="mw-page-title-main">Subacute thyroiditis</span> Medical condition

Subacute thyroiditis refers to a temporal classification of the different forms of thyroiditis based on onset of symptoms. The temporal classification of thyroiditis includes presentation of symptoms in an acute, subacute, or chronic manner. There are also other classification systems for thyroiditis based on factors such as clinical symptoms and underlying etiology.

<span class="mw-page-title-main">Hypothalamic–pituitary–thyroid axis</span> Part of the neuroendocrine system

The hypothalamic–pituitary–thyroid axis is part of the neuroendocrine system responsible for the regulation of metabolism and also responds to stress.

<span class="mw-page-title-main">Hashimoto's encephalopathy</span> Human disease (neurological condition)

Hashimoto's encephalopathy, also known as steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT), is a neurological condition characterized by encephalopathy, thyroid autoimmunity, and good clinical response to corticosteroids. It is associated with Hashimoto's thyroiditis, and was first described in 1966. It is sometimes referred to as a neuroendocrine disorder, although the condition's relationship to the endocrine system is widely disputed. It is recognized as a rare disease by the NIH Genetic and Rare Diseases Information Center.

Euthyroid sick syndrome (ESS) is a state of adaptation or dysregulation of thyrotropic feedback control wherein the levels of T3 and/or T4 are abnormal, but the thyroid gland does not appear to be dysfunctional. This condition may result from allostatic responses of hypothalamus-pituitary-thyroid feedback control, dyshomeostatic disorders, drug interferences, and impaired assay characteristics in critical illness.

Thyroid disease in pregnancy can affect the health of the mother as well as the child before and after delivery. Thyroid disorders are prevalent in women of child-bearing age and for this reason commonly present as a pre-existing disease in pregnancy, or after childbirth. Uncorrected thyroid dysfunction in pregnancy has adverse effects on fetal and maternal well-being. The deleterious effects of thyroid dysfunction can also extend beyond pregnancy and delivery to affect neurointellectual development in the early life of the child. Due to an increase in thyroxine binding globulin, an increase in placental type 3 deioidinase and the placental transfer of maternal thyroxine to the fetus, the demand for thyroid hormones is increased during pregnancy. The necessary increase in thyroid hormone production is facilitated by high human chorionic gonadotropin (hCG) concentrations, which bind the TSH receptor and stimulate the maternal thyroid to increase maternal thyroid hormone concentrations by roughly 50%. If the necessary increase in thyroid function cannot be met, this may cause a previously unnoticed (mild) thyroid disorder to worsen and become evident as gestational thyroid disease. Currently, there is not enough evidence to suggest that screening for thyroid dysfunction is beneficial, especially since treatment thyroid hormone supplementation may come with a risk of overtreatment. After women give birth, about 5% develop postpartum thyroiditis which can occur up to nine months afterwards. This is characterized by a short period of hyperthyroidism followed by a period of hypothyroidism; 20–40% remain permanently hypothyroid.

Antithyroid autoantibodies (or simply antithyroid antibodies) are autoantibodies targeted against one or more components on the thyroid. The most clinically relevant anti-thyroid autoantibodies are anti-thyroid peroxidase antibodies (anti-TPO antibodies, TPOAb), thyrotropin receptor antibodies (TRAb) and thyroglobulin antibodies (TgAb). TRAb's are subdivided into activating, blocking and neutral antibodies, depending on their effect on the TSH receptor. Anti-sodium/iodide (Anti–Na+/I−) symporter antibodies are a more recent discovery and their clinical relevance is still unknown. Graves' disease and Hashimoto's thyroiditis are commonly associated with the presence of anti-thyroid autoantibodies. Although there is overlap, anti-TPO antibodies are most commonly associated with Hashimoto's thyroiditis and activating TRAb's are most commonly associated with Graves' disease. Thyroid microsomal antibodies were a group of anti-thyroid antibodies; they were renamed after the identification of their target antigen (TPO).

The sum activity of peripheral deiodinases is the maximum amount of triiodothyronine produced per time-unit under conditions of substrate saturation. It is assumed to reflect the activity of deiodinases outside the central nervous system and other isolated compartments. GD is therefore expected to reflect predominantly the activity of type I deiodinase.

<span class="mw-page-title-main">Jostel's TSH index</span>

Jostel's TSH index, also referred to as Jostel's thyrotropin index or Thyroid Function index (TFI), is a method for estimating the thyrotropic function of the anterior pituitary lobe in a quantitative way. The equation has been derived from the logarithmic standard model of thyroid homeostasis. In a paper from 2014 further study was suggested to show if it is useful, but the 2018 guideline by the European Thyroid Association for the diagnosis of uncertain cases of central hypothyroidism regarded it as beneficial. It is also recommended for purposes of differential diagnosis in the sociomedical expert assessment.

<span class="mw-page-title-main">SimThyr</span> Medical research simulation software

SimThyr is a free continuous dynamic simulation program for the pituitary-thyroid feedback control system. The open-source program is based on a nonlinear model of thyroid homeostasis. In addition to simulations in the time domain the software supports various methods of sensitivity analysis. Its simulation engine is multi-threaded and supports multiple processor cores. SimThyr provides a GUI, which allows for visualising time series, modifying constant structure parameters of the feedback loop, storing parameter sets as XML files and exporting results of simulations in various formats that are suitable for statistical software. SimThyr is intended for both educational purposes and in-silico research.

The Thyrotroph Thyroid Hormone Sensitivity Index is a calculated structure parameter of thyroid homeostasis. It was originally developed to deliver a method for fast screening for resistance to thyroid hormone. Today it is also used to get an estimate for the set point of thyroid homeostasis, especially to assess dynamic thyrotropic adaptation of the anterior pituitary gland, including non-thyroidal illnesses.

The Thyroid Feedback Quantile-based Index (TFQI) is a calculated parameter for thyrotropic pituitary function. It was defined to be more robust to distorted data than established markers including Jostel's TSH index (JTI) and the thyrotroph thyroid hormone sensitivity index (TTSI).

References

  1. ↑ Hoermann R, Midgley J, Larisch R, Dietrich JW (4 August 2021). "Treatment options for subclinical hypothyroidism". European Journal of Endocrinology. 185 (3): L5–L6. doi: 10.1530/EJE-20-1405 . PMID   34243143.
  2. 1 2 3 4 5 6 7 8 9 10 11 Dietrich, J. W. (2002). Der Hypophysen-Schilddrüsen-Regelkreis. Berlin, Germany: Logos-Verlag Berlin. ISBN   978-3-89722-850-4. OCLC   50451543. OL   24586469M.
  3. 1 2 3 4 5 Dietrich JW, Landgrafe-Mende G, Wiora E, Chatzitomaris A, Klein HH, Midgley JE, Hoermann R (9 June 2016). "Calculated Parameters of Thyroid Homeostasis: Emerging Tools for Differential Diagnosis and Clinical Research". Frontiers in Endocrinology. 7: 57. doi: 10.3389/fendo.2016.00057 . PMC   4899439 . PMID   27375554.
  4. ↑ Bierich JR (1964). "Endokrinologie". In H. Wiesener (ed.). Einführung in die Entwicklungsphysiologie des Kindes. Springer. p. 310. ISBN   978-3-642-86507-7.
  5. ↑ Thompson MA (June 2001). "Radiation safety precautions in the management of the hospitalized (131)I therapy patient". Journal of Nuclear Medicine Technology. 29 (2): 61–6, test 74–5. PMID   11376097.
  6. ↑ Dietrich JW, Stachon A, Antic B, Klein HH, Hering S (Oct 2008). "The AQUA-FONTIS study: protocol of a multidisciplinary, cross-sectional and prospective longitudinal study for developing standardized diagnostics and classification of non-thyroidal illness syndrome". BMC Endocrine Disorders. 8 (1): 13. doi: 10.1186/1472-6823-8-13 . PMC   2576461 . PMID   18851740.
  7. 1 2 3 Hoermann R, Midgley JE, Larisch R, Dietrich JW (18 August 2016). "Relational Stability of Thyroid Hormones in Euthyroid Subjects and Patients with Autoimmune Thyroid Disease". European Thyroid Journal. 5 (3): 171–179. doi:10.1159/000447967. PMC   5091265 . PMID   27843807.
  8. 1 2 3 Krysiak R, Marek B, Okopień B (2019). "Sexual function and depressive symptoms in men with overt hyperthyroidism". Endokrynologia Polska. 70 (1): 64–71. doi: 10.5603/EP.a2018.0069 . PMID   30307028.
  9. 1 2 3 Aweimer A, Schiedat F, Schöne D, Landgrafe-Mende G, Bogossian H, Mügge A, Patsalis PC, Gotzmann M, Akin I, El-Battrawy I, Dietrich JW (23 November 2021). "Abnormal Cardiac Repolarization in Thyroid Diseases: Results of an Observational Study". Frontiers in Cardiovascular Medicine. 8: 738517. doi: 10.3389/fcvm.2021.738517 . PMC   8649843 . PMID   34888359.
  10. ↑ Dietrich J, Fischer M, Jauch J, Pantke E, Gärtner R, Pickardt CR. "SPINA-THYR: A Novel Systems Theoretic Approach to Determine the Secretion Capacity of the Thyroid Gland". European Journal of Internal Medicine. 10 (Suppl. 1): S34.
  11. ↑ Dietrich JW (Sep 2012). "Thyroid storm". Medizinische Klinik, Intensivmedizin und Notfallmedizin. 107 (6): 448–53. doi:10.1007/s00063-012-0113-2. PMID   22878518. S2CID   31285541.
  12. ↑ Wang X, Liu H, Chen J, Huang Y, Li L, Rampersad S, Qu S (21 April 2016). "Metabolic Characteristics in Obese Patients Complicated by Mild Thyroid Hormone Deficiency". Hormone and Metabolic Research. 48 (5): 331–7. doi: 10.1055/s-0042-105150 . PMID   27101096.
  13. 1 2 Hoermann R, Midgley J, Larisch R, Dietrich JW (19 July 2018). "The Role of Functional Thyroid Capacity in Pituitary Thyroid Feedback Regulation". European Journal of Clinical Investigation. 48 (10): e13003. doi:10.1111/eci.13003. PMID   30022470. S2CID   51698223.
  14. 1 2 Kim MJ, Cho SW, Choi S, Ju DL, Park DJ, Park YJ (2018). "Changes in Body Compositions and Basal Metabolic Rates during Treatment of Graves' Disease". International Journal of Endocrinology. 2018: 9863050. doi: 10.1155/2018/9863050 . PMC   5960571 . PMID   29853888.
  15. ↑ Steinberger E, Pilz S, Trummer C, Theiler-Schwetz V, Reichhartinge M, Benninger T, Pandis M, Malle O, Keppel MH, Verheyen N, Grübler MR, Voelkl J, Meinitzer A, März W (4 September 2020). "Associations of Thyroid Hormones and Resting Heart Rate in Patients Referred to Coronary Angiography". Hormone and Metabolic Research. 52 (12): a–1232–7292. doi:10.1055/a-1232-7292. PMID   32886945. S2CID   221502851.
  16. ↑ Zhang L, Li J, Zhang S, Su C, Su Z, Zhang Y, Gai Y, Shao S, Li J, Zhang G (30 July 2022). "Study of the Associations between Color Doppler Ultrasound Grading of Hyperthyroidism and Biochemical Data on Thyroid Function". International Journal of Endocrinology. 2022: 1–6. doi: 10.1155/2022/9743654 . PMC   9356896 . PMID   35942151.
  17. ↑ Krysiak R, Kowalcze K, Okopień B (20 May 2019). "The Effect of Selenomethionine on Thyroid Autoimmunity in Euthyroid Men With Hashimoto Thyroiditis and Testosterone Deficiency". Journal of Clinical Pharmacology. 59 (11): 1477–1484. doi:10.1002/jcph.1447. PMID   31106856. S2CID   159040151.
  18. ↑ Dietrich JW, Landgrafe G, Fotiadou EH (2012). "TSH and Thyrotropic Agonists: Key Actors in Thyroid Homeostasis". Journal of Thyroid Research. 2012: 351864. doi: 10.1155/2012/351864 . PMC   3544290 . PMID   23365787.
  19. 1 2 Larisch R, Midgley J, Dietrich JW, Hoermann R (23 January 2024). "Effect of Radioiodine Treatment on Quality of Life in Patients with Subclinical Hyperthyroidism: A Prospective Controlled Study". Nuklearmedizin. Nuclear Medicine. 63 (3): 176–187. doi:10.1055/a-2240-8087. PMID   38262472. S2CID   267198748.
  20. ↑ Dietrich JW, Schifferdecker E, Schatz H, Klein H (2022). "Endokrine und Stoffwechseldiagnostik". Die Ärztliche Begutachtung. Springer Reference Medizin. pp. 1–13. doi:10.1007/978-3-662-61937-7_83-1. ISBN   978-3-662-61937-7.
  21. ↑ Rosolowska-Huszcz D, Kozlowska L, Rydzewski A (Aug 2005). "Influence of low protein diet on nonthyroidal illness syndrome in chronic renal failure". Endocrine. 27 (3): 283–8. doi:10.1385/endo:27:3:283. PMID   16230785. S2CID   25630198.
  22. ↑ Yang S, Lai S, Wang Z, Liu A, Wang W, Guan H (December 2021). "Thyroid Feedback Quantile-based Index correlates strongly to renal function in euthyroid individuals". Annals of Medicine. 53 (1): 1945–1955. doi:10.1080/07853890.2021.1993324. PMC   8567884 . PMID   34726096.
  23. ↑ Liu S, Ren J, Zhao Y, Han G, Hong Z, Yan D, Chen J, Gu G, Wang G, Wang X, Fan C, Li J (2013). "Nonthyroidal Illness Syndrome: is it Far Away From Crohn's Disease?". Journal of Clinical Gastroenterology. 47 (2): 153–9. doi:10.1097/MCG.0b013e318254ea8a. PMID   22874844. S2CID   35344744.
  24. ↑ Wan S, Yang J, Gao X, Zhang L, Wang X (22 July 2020). "Nonthyroidal Illness Syndrome in Patients With Short-Bowel Syndrome". Journal of Parenteral and Enteral Nutrition. 45 (5): 973–981. doi:10.1002/jpen.1967. PMID   32697347. S2CID   220698496.
  25. ↑ Dietrich JW, Ackermann A, Kasippillai A, Kanthasamy Y, Tharmalingam T, Urban A, Vasileva S, Schildhauer TA, Klein HH, Stachon A, Hering S (19 September 2019). "Adaptive Veränderungen des Schilddrüsenstoffwechsels als Risikoindikatoren bei Traumata". Trauma und Berufskrankheit. 21 (4): 260–267. doi:10.1007/s10039-019-00438-z. S2CID   202673793.
  26. ↑ Ruiz-Núñez B, Tarasse R, Vogelaar EF, Janneke Dijck-Brouwer DA, Muskiet FA (20 March 2018). "Higher Prevalence of "Low T3 Syndrome" in Patients With Chronic Fatigue Syndrome: A Case–Control Study". Frontiers in Endocrinology. 9: 97. doi: 10.3389/fendo.2018.00097 . PMC   5869352 . PMID   29615976.
  27. ↑ Sun Q, Oltra E, Dijck-Brouwer D, Chillon TS, Seemann P, Asaad S, Demircan K, Espejo-Oltra JA, Sánchez-Fito T, Martín-Martínez E, Minich WB, Muskiet F, Schomburg L (3 July 2023). "Autoantibodies to selenoprotein P in chronic fatigue syndrome suggest selenium transport impairment and acquired resistance to thyroid hormone". Redox Biology. 65: 102796. doi:10.1016/j.redox.2023.102796. PMC   10338150 . PMID   37423160.
  28. ↑ Bingyan Z, Dong W (7 July 2019). "Impact of thyroid hormones on asthma in older adults". Journal of International Medical Research. 47 (9): 4114–4125. doi:10.1177/0300060519856465. PMC   6753544 . PMID   31280621.
  29. 1 2 Wu K, Zhou Y, Ke S, Huang J, Gao X, Li B, Lin X, Liu X, Liu X, Ma L, Wang L, Wu L, Wu L, Xie C, Xu J, Wang Y, Liu L (December 2021). "Lifestyle is associated with thyroid function in subclinical hypothyroidism: a cross-sectional study". BMC Endocrine Disorders. 21 (1): 112. doi: 10.1186/s12902-021-00772-z . PMC   8161919 . PMID   34049544.
  30. ↑ Zhou Y, Ke S, Wu K, Huang J, Gao X, Li B, Lin X, Liu X, Liu X, Ma L, Wang L, Wu L, Wu L, Xie C, Xu J, Wang Y, Liu L (2021-05-29). "Correlation between Thyroid Homeostasis and Obesity in Subclinical Hypothyroidism: Community-Based Cross-Sectional Research". International Journal of Endocrinology. 2021: 1–7. doi: 10.1155/2021/6663553 . PMC   8179776 . PMID   34135958.
  31. ↑ Yang L, Sun X, Tao H, Zhao Y (February 2023). "The association between thyroid homeostasis parameters and obesity in subjects with euthyroidism". Journal of Physiology and Pharmacology. 74 (1). doi:10.26402/jpp.2023.1.07. PMID   37245234.
  32. ↑ Ittermann T, Markus M, Bahls M, Felix SB, Steveling A, Nauck M, Völzke H, Dörr M (2021-05-18). "Low serum TSH levels are associated with low values of fat-free mass and body cell mass in the elderly". Scientific Reports. 11 (1): 10547. Bibcode:2021NatSR..1110547I. doi: 10.1038/s41598-021-90178-7 . PMC   8131378 . PMID   34006958.
  33. ↑ Krysiak R, Szkróbka W, Okopień B (June 2018). "Sex-Dependent Effect of Metformin on Serum Prolactin Levels In Hyperprolactinemic Patients With Type 2 Diabetes: A Pilot Study". Experimental and Clinical Endocrinology & Diabetes. 126 (6): 342–348. doi:10.1055/s-0043-122224. PMID   29169197. S2CID   43144838.
  34. ↑ Krysiak R, Kowalcze K, Okopień B (5 December 2023). "Impact of metformin on hypothalamic-pituitary-thyroid axis activity in women with autoimmune and non-autoimmune subclinical hypothyroidism: a pilot study". Pharmacological Reports. 76 (1): 195–206. doi: 10.1007/s43440-023-00556-3 . PMC   10830717 . PMID   38051473.
  35. 1 2 Krysiak R, Szkróbka W, Okopień B (6 August 2019). "The Impact of Testosterone on Metformin Action on Hypothalamic-Pituitary-Thyroid Axis Activity in Men: A Pilot Study". Journal of Clinical Pharmacology. 60 (2): 164–171. doi:10.1002/jcph.1507. PMID   31389032. S2CID   199466858.
  36. ↑ Krysiak R, Kowalcze K, Okopień B (November 2021). "The impact of metformin on hypothalamic-pituitary-thyroid axis activity in postmenopausal women with untreated non-autoimmune subclinical hypothyroidism". Clinical and Experimental Pharmacology & Physiology. 48 (11): 1469–1476. doi:10.1111/1440-1681.13542. PMID   34145615. S2CID   235481699.
  37. ↑ Krysiak R, Kowalcze K, Wolnowska M, Okopień B (5 January 2020). "The impact of oral hormonal contraception on metformin action on hypothalamic-pituitary-thyroid axis activity in women with diabetes and prediabetes: A pilot study". Journal of Clinical Pharmacy and Therapeutics. 45 (5): 937–945. doi: 10.1111/jcpt.13105 . PMID   31903641. S2CID   209895460.
  38. ↑ Krysiak R, Kowalcze K, Okopień B (9 January 2019). "Sexual function and depressive symptoms in young women with overt hyperthyroidism". European Journal of Obstetrics, Gynecology, and Reproductive Biology. 234: 43–48. doi:10.1016/j.ejogrb.2018.12.035. PMID   30654201. S2CID   58558358.
  39. ↑ Krysiak R, Kowalcze K, Okopień B (10 June 2019). "The effect of testosterone on thyroid autoimmunity in euthyroid men with Hashimoto's thyroiditis and low testosterone levels". Journal of Clinical Pharmacy and Therapeutics. 44 (5): 742–749. doi: 10.1111/jcpt.12987 . PMID   31183891. S2CID   184487697.
  40. 1 2 Cui T, Qi Z, Wang M, Zhang X, Wen W, Gao S, Zhai J, Guo C, Zhang N, Zhang X, Guan Y, Retnakaran R, Hao W, Zhai D, Zhang R, Zhao Y, Wen SW (April 2024). "Thyroid allostasis in drug-free affective disorder patients". Psychoneuroendocrinology. 162: 106962. doi:10.1016/j.psyneuen.2024.106962. PMID   38277991.
  41. 1 2 Abu Rached N, Dietrich JW, Ocker L, Quast DR, Scheel C, Gambichler T, Bechara FG (4 December 2023). "Primary Thyroid Dysfunction Is Prevalent in Hidradenitis Suppurativa and Marked by a Signature of Hypothyroid Graves' Disease: A Case–Control Study". Journal of Clinical Medicine. 12 (23): 7490. doi: 10.3390/jcm12237490 . PMC   10707714 . PMID   38068542.
  42. ↑ Krysiak R, Szkróbka W, Okopień B (30 July 2018). "The Effect of Gluten-Free Diet on Thyroid Autoimmunity in Drug-Naïve Women with Hashimoto's Thyroiditis: A Pilot Study". Experimental and Clinical Endocrinology & Diabetes. 127 (7): 417–422. doi: 10.1055/a-0653-7108 . PMID   30060266. S2CID   51874521.
  43. ↑ Krysiak R, Szkróbka W, Okopień B (27 August 2018). "The Relationship Between Statin Action On Thyroid Autoimmunity And Vitamin D Status: A Pilot Study". Experimental and Clinical Endocrinology & Diabetes. 127 (1): 23–28. doi:10.1055/a-0669-9309. PMID   30149415. S2CID   52100009.
  44. 1 2 Krysiak R, Szkróbka W, Okopień B (October 2018). "The effect of vitamin D and selenomethionine on thyroid antibody titers, hypothalamic-pituitary-thyroid axis activity and thyroid function tests in men with Hashimoto's thyroiditis: a pilot study". Pharmacological Reports. 71 (2): 243–7. doi:10.1016/j.pharep.2018.10.012. PMID   30818086. S2CID   73481267.
  45. 1 2 Krysiak R, Kowalcze K, Okopień B (December 2018). "Selenomethionine potentiates the impact of vitamin D on thyroid autoimmunity in euthyroid women with Hashimoto's thyroiditis and low vitamin D status". Pharmacological Reports. 71 (2): 367–73. doi:10.1016/j.pharep.2018.12.006. PMID   30844687. S2CID   73486105.
  46. ↑ Krysiak R, Kowalcze K, Okopień B (April 2019). "The effect of vitamin D on thyroid autoimmunity in euthyroid men with autoimmune thyroiditis and testosterone deficiency". Pharmacological Reports. 71 (5): 798–803. doi:10.1016/j.pharep.2019.04.010. PMID   31377561.
  47. ↑ Krysiak R, Kowalcze K, Szkróbka W, Okopień B (20 June 2023). "Sexual Function and Depressive Symptoms in Young Women with Euthyroid Hashimoto's Thyroiditis Receiving Vitamin D, Selenomethionine and Myo-Inositol: A Pilot Study". Nutrients. 15 (12): 2815. doi: 10.3390/nu15122815 . PMC   10304218 . PMID   37375719.
  48. ↑ Krysiak R, Kowalcze K, Okopień B (30 June 2022). "The impact of vitamin D on thyroid autoimmunity and hypothalamic-pituitary-thyroid axis activity in myo-inositol-treated and myo-inositol-naïve women with autoimmune thyroiditis: A pilot study". Journal of Clinical Pharmacy and Therapeutics. 47 (11): 1759–1767. doi: 10.1111/jcpt.13730 . PMID   35775148. S2CID   250174449.
  49. ↑ Saini C (6 April 2021). "Autoimmune thyroiditis and multiple nutritional factors". International Journal of Endocrinology (Ukraine). 16 (8): 648–653. doi: 10.22141/2224-0721.16.8.2020.222885 .
  50. ↑ Krysiak R, Szkróbka W, Okopień B (February 2021). "Dehydroepiandrosterone potentiates the effect of vitamin D on thyroid autoimmunity in euthyroid women with autoimmune thyroiditis: A pilot study". Clinical and Experimental Pharmacology & Physiology. 48 (2): 195–202. doi:10.1111/1440-1681.13410. PMID   33007106. S2CID   222165571.
  51. ↑ Krysiak R, Kowalcze K, Okopień B (2021-06-09). "The impact of exogenous vitamin D on thyroid autoimmunity in euthyroid men with autoimmune thyroiditis and early-onset androgenic alopecia". Pharmacological Reports. 73 (5): 1439–1447. doi: 10.1007/s43440-021-00295-3 . PMC   8460519 . PMID   34106452.
  52. ↑ Krysiak R, Kowalcze K, Okopień B (10 July 2020). "Hyperprolactinaemia attenuates the inhibitory effect of vitamin D/selenomethionine combination therapy on thyroid autoimmunity in euthyroid women with Hashimoto's thyroiditis: A pilot study". Journal of Clinical Pharmacy and Therapeutics. 45 (6): 1334–1341. doi: 10.1111/jcpt.13214 . PMID   32649802. S2CID   220485158.
  53. ↑ Krysiak R, Kowalcze K, Okopień B (6 October 2022). "Gluten-free diet attenuates the impact of exogenous vitamin D on thyroid autoimmunity in young women with autoimmune thyroiditis: a pilot study". Scandinavian Journal of Clinical and Laboratory Investigation. 82 (7–8): 518–524. doi:10.1080/00365513.2022.2129434. PMID   36200764. S2CID   252736895.
  54. 1 2 Krysiak R, Kowalcze K, Okopień B (14 September 2019). "The effect of spironolactone on thyroid autoimmunity in euthyroid men with Hashimoto's thyroiditis". Journal of Clinical Pharmacy and Therapeutics. 45 (1): 152–159. doi: 10.1111/jcpt.13046 . PMID   31520539.
  55. ↑ Yang L, Sun X, Zhao Y, Tao H (7 March 2022). "Effects of Antihypertensive Drugs on Thyroid Function in Type 2 Diabetes Patients With Euthyroidism". Frontiers in Pharmacology. 13: 802159. doi: 10.3389/fphar.2022.802159 . PMC   8940167 . PMID   35330837.
  56. ↑ Chen Y, Zhang W, Chen C, Wang Y, Wang N, Lu Y (31 March 2022). "Thyroid and bone turnover markers in type 2 diabetes: results from the METAL study". Endocrine Connections. 11 (3). doi:10.1530/EC-21-0484. PMC   9010813 . PMID   35196256.
  57. ↑ Li W, He Q, Zhang H, Shu S, Wang L, Wu Y, Yuan Z, Zhou J (20 January 2023). "Thyroid-stimulating hormone within the normal reference range has a U-shaped association with the severity of coronary artery disease in nondiabetic patients but is diluted in diabetic patients". Journal of Investigative Medicine. 71 (4): 350–360. doi:10.1177/10815589221149187. PMID   36680358. S2CID   256055662.
  58. ↑ Bazika-Gerasch B, Kumowski N, Enax-Krumova E, Kaisler M, Eitner LB, Maier C, Dietrich JW (29 May 2024). "Impaired autonomic function and somatosensory disturbance in patients with treated autoimmune thyroiditis". Scientific Reports. 14 (1): 12358. Bibcode:2024NatSR..1412358B. doi:10.1038/s41598-024-63158-w. PMC   11137073 . PMID   38811750.
  59. 1 2 Müller P, Dietrich JW, Lin T, Bejinariu A, Binnebößel S, Bergen F, Schmidt J, Müller SK, Chatzitomaris A, Kurt M, Gerguri S, Clasen L, Klein HH, Kelm M, Makimoto H (January 2020). "Usefulness of Serum Free Thyroxine Concentration to Predict Ventricular Arrhythmia Risk in Euthyroid Patients with Structural Heart Disease". The American Journal of Cardiology. 125 (8): 1162–1169. doi:10.1016/j.amjcard.2020.01.019. PMID   32087999. S2CID   211261823.
  60. ↑ Aweimer A, El-Battrawy I, Akin I, Borggrefe M, Mügge A, Patsalis PC, Urban A, Kummer M, Vasileva S, Stachon A, Hering S, Dietrich JW (12 November 2020). "Abnormal thyroid function is common in takotsubo syndrome and depends on two distinct mechanisms: results of a multicentre observational study". Journal of Internal Medicine. 289 (5): 675–687. doi: 10.1111/joim.13189 . PMID   33179374.
  61. ↑ Aweimer A, Dietrich JW, Santoro F, Fàbregas MC, Mügge A, Núñez-Gil IJ, Vazirani R, Vedia O, Pätz T, Ragnatela I, Arcari L, Volpe M, Corbì-Pascual M, Martinez-Selles M, Almendro-Delia M, Sionis A, Uribarri A, Thiele H, Brunetti ND, Eitel I, Stiermaier T, Hamdani N, Abumayyaleh M, Akin I, El-Battrawy I (18 March 2024). "Takotsubo syndrome outcomes predicted by thyroid hormone signature: insights from cluster analysis of a multicentre registry". eBioMedicine. 102: 105063. doi:10.1016/j.ebiom.2024.105063. PMC   10963195 . PMID   38502972.
  62. ↑ Aweimer A, Engemann L, Amar S, Ewers A, Afshari F, Maiß C, Kern K, Lücke T, Mügge A, El-Battrawy I, Dietrich JW, Brüne M (24 October 2023). "Stress-Mediated Abnormalities in Regional Myocardial Wall Motion in Young Women with a History of Psychological Trauma". Journal of Clinical Medicine. 12 (21): 6702. doi: 10.3390/jcm12216702 . PMC   10647814 . PMID   37959168.
  63. ↑ Gürdal A, Eroğlu H, Helvaci F, Sümerkan MÇ, Kasali K, Çetin Ş, Aksan G, Kiliçkesmez K (March 2017). "Evaluation of Tp-e interval, Tp-e/QT ratio and Tp-e/QTc ratio in patients with subclinical hypothyroidism". Therapeutic Advances in Endocrinology and Metabolism. 8 (3): 25–32. doi:10.1177/2042018816684423. PMC   5363453 . PMID   28377800.
  64. ↑ Tan Y, Gao L, Yin Q, Sun Z, Man X, Du Y, Chen Y (April 2021). "Thyroid hormone levels and structural parameters of thyroid homeostasis are correlated with motor subtype and disease severity in euthyroid patients with Parkinson's disease". The International Journal of Neuroscience. 131 (4): 346–356. doi:10.1080/00207454.2020.1744595. PMID   32186220. S2CID   212752563.
  65. ↑ Hoermann R, Midgley JE, Larisch R, Dietrich JW (7 November 2016). "Relational Stability in the Expression of Normality, Variation, and Control of Thyroid Function". Frontiers in Endocrinology. 7: 142. doi: 10.3389/fendo.2016.00142 . PMC   5098235 . PMID   27872610.
  66. 1 2 Yang S, Sun J, Wang S, E L, Zhang S, Jiang X (9 August 2023). "Association of exposure to polycyclic aromatic hydrocarbons with thyroid hormones in adolescents and adults, and the influence of the iodine status". Environmental Science: Processes & Impacts. 25 (9): 1449–1463. doi:10.1039/d3em00135k. PMID   37555279. S2CID   259916981.
  67. ↑ Kim MJ, Kim S, Choi S, Lee I, Moon MK, Choi K, Park YJ, Cho YH, Kwon YM, Yoo J, Cheon GJ, Park J (December 2020). "Association of exposure to polycyclic aromatic hydrocarbons and heavy metals with thyroid hormones in general adult population and potential mechanisms". Science of the Total Environment. 762: 144227. doi:10.1016/j.scitotenv.2020.144227. PMID   33373756. S2CID   229722026.
  68. ↑ Chen Y, Zhang W, Chen J, Wang N, Chen C, Wang Y, Wan H, Chen B, Lu Y (2021). "Association of Phthalate Exposure with Thyroid Function and Thyroid Homeostasis Parameters in Type 2 Diabetes". Journal of Diabetes Research. 2021: 4027380. doi: 10.1155/2021/4027380 . PMC   8566079 . PMID   34746318.
  69. ↑ Maric D, Baralic K, Javorac D, Mandic-Rajcevic S, Zarkovic M, Antonijevic B, Djukic-Cosic D, Bulat Z, Djordjevic AB (2023). "Nickel as a potential disruptor of thyroid function: benchmark modelling of human data". Frontiers in Endocrinology. 14: 1145153. doi: 10.3389/fendo.2023.1145153 . PMC   10549921 . PMID   37800147.
  70. ↑ Huang PC, Chen HC, Leung SH, Lin YJ, Huang HB, Chang WT, Huang HI, Chang JW (1 December 2023). "Associations between paraben exposure, thyroid capacity, homeostasis and pituitary thyrotropic function in the general Taiwanese: Taiwan Environmental Survey for Toxicants (TEST) 2013". Environmental Science and Pollution Research. 31 (1): 1288–1303. doi:10.1007/s11356-023-31277-y. PMID   38038926. S2CID   265514578.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.